Every 10-Q that Mereo BioPharma Group plc American (MREO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MREO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MREO filings page.
Mereo BioPharma Group plc reported a six‑month 2026 net loss of $13.7 million, an improvement from $27.5 million a year earlier, with no product revenue and operating expenses focused on rare‑disease programs setrusumab and alvelestat. Cash and cash equivalents were $30.1 million at June 30, 2026, versus $56.1 million at June 30, 2025, supporting management’s expectation that current resources will fund operations into late 2027.
Research and development spending fell to $6.6 million for the first half from $9.3 million, and general and administrative expenses declined to $9.2 million from $12.8 million, reflecting delayed and reduced pre‑commercial and development activities. Foreign currency movements contributed a $1.3 million gain versus an $8.1 million loss in the prior‑year period.
As a subsequent event, Mereo entered an option and license agreement with Sentynl Therapeutics granting U.S. commercial and global manufacturing rights to alvelestat. On option exercise, Mereo would be eligible for $40 million in upfront and R&D payments, up to $435 million in milestones, and double‑digit tiered U.S. royalties, while leading the global Phase 3 study.
Mereo BioPharma Group plc reported a Q3 2025 net loss of $7.0 million, reduced from $15.0 million a year earlier, equal to a basic and diluted loss per share of $0.01 versus $0.02.
Revenue was minimal, with $500,000 recognized in the first nine months of 2025 from a leflutrozole milestone payment under the ReproNovo licensing agreement. Research and development expenses in Q3 rose to $4.3 million from $3.2 million, driven mainly by higher spending on setrusumab and alvelestat. General and administrative expenses were broadly stable at about $6.0 million in the quarter.
As of September 30, 2025, Mereo held cash and cash equivalents of $48.7 million, with total assets of $53.6 million and shareholders’ equity of $46.6 million. Management states that existing cash is expected to fund operations into 2027. During 2025, a Novartis convertible loan note was fully converted into ordinary shares, removing this debt and associated interest expense.
Mereo BioPharma Group plc reported several financing and collaboration items including a £0.265 convertible loan note held by Novartis that was convertible at holder discretion and bore 9% interest with a maturity date of February 10, 2025. The company issued two tranches of Novartis warrants (2,000,000 in 2023 plus a 2020 tranche) exercisable at £0.265 until February 2028; warrants were recognized as equity instruments. The company issued ordinary shares to AstraZeneca as part of an amended license agreement and received an aggregate upfront payment of $5.0 million, plus a $0.5 million milestone paid upon execution, and issued additional shares later. Outstanding warrants equal approximately 0.3% of issued share capital as of June 30, 2025 (0.4% as of December 31, 2024). The filing discloses milestone receipts of $50.0 million under Ultragenyx (setrusumab), $4.0 million under Feng Biosciences (navicixizumab), and $1.0 million under ReproNovo (leflutrozole), plus later milestone payments noted. The company lists a range of development, regulatory, manufacturing, commercialization and intellectual property costs and risks that could affect timing and cash needs.